Avid Pro Tools Delivers Higher Video Resolution and Frame Rates, Streamlining Film and TV Post-Production Workflows
BURLINGTON, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) — Avid® (Nasdaq: AVID) today announced that the newest version of Pro Tools® […]
Announcing the Low-code50
TYSONS CORNER, Va., Oct. 16, 2019 (GLOBE NEWSWIRE) — New independent research from Influencer50, Inc. identifies the “Low-code50,” a list […]
dynaCERT Establishes Strategic Alliance with MOSOLF Group of Europe
TORONTO, Oct. 16, 2019 (GLOBE NEWSWIRE) — dynaCERT Inc. (TSX VENTURE: DYA) (OTCQB: DYFSF) (FRA: DMJ) (“dynaCERT” or the “Company”) […]
Ctrip Group Shares Marketing Tips at ITB Asia 2019
SINGAPORE, Oct. 16, 2019 (GLOBE NEWSWIRE) — Today, representatives from the Ctrip and Trip.com brands participated in the 12th ITB […]
Progressive Reports September 2019 Results
MAYFIELD VILLAGE, OHIO, Oct. 16, 2019 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for September […]
Lifetime Brands to Host Investor Day on November 14, 2019
GARDEN CITY, N.Y., Oct. 16, 2019 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and […]
Applied Optoelectronics to Announce Third Quarter 2019 Financial Results
SUGAR LAND, Texas, Oct. 16, 2019 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (NASDAQ:AAOI), a leading provider of fiber-optic access network […]
HomeTrust Bancshares, Inc. Announces the Completion of Previous Stock Repurchase Program and the Authorization of a New Stock Repurchase Program
ASHEVILLE, N.C., Oct. 16, 2019 (GLOBE NEWSWIRE) — HomeTrust Bancshares, Inc. (the “Company”) (NASDAQ: HTBI), the holding company for HomeTrust […]
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology
SEATTLE and ENCINO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel […]
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% […]
